Skip to content

Transradial-Band Pilot Study

Optimization of Transradial-Band Removal Following Transradial Arterial Access for Interventional Radiology Diagnostic and Interventional Procedures (A Pilot Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04709341
Enrollment
30
Registered
2021-01-14
Start date
2021-02-03
Completion date
2024-02-20
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radial Artery Incision Site Closure

Brief summary

In the study group, the TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals. In the standard of care group, the TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals. The aim of the study is to reduce the time the device is in place while minimizing potential complications.

Interventions

DEVICETR Band 60MIN

TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals

DEVICETR Band 120MIN

TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years and older * Have an acceptable Barbeau test (i.e. type A through C) * Have acceptable coagulation parameters (based on PT, INR, platelet count, and appropriate pre-procedural management of anticoagulants, See Table 1) * The caliber of the left radial artery based on a pre-procedure sonographic evaluation will need to be greater than or equal to 1.6 mm. * The appropriate pre-procedural management of anticoagulants is based on the consensus guidelines established by Patel et al16. * INR less than 1.5 * Platelet count greater than 50,000 platelet/uL * Prothrombin time less than 15 seconds

Exclusion criteria

* If there is an unacceptable risk of bleeding diathesis, or * If he or she is not a suitable candidate for transradial access based on a Barbeau test type D or a diameter of the left radial artery less than 1.6 mm.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants With Bleedingan average of 12 hours post procedureContinued ooze requiring re-inflation of the TR-Band or subcutaneous ecchymosis without a discernable hematoma
Left Radial Artery Occlusion30 days post procedureReduced or absence of radial artery blood flow based on ultrasound and Barbeau test

Countries

United States

Participant flow

Recruitment details

The study was conducted at MUSC's VIR Department, including University Hospital and outpatient clinics. Patients scheduled for angiographic procedures were screened for eligibility via Barbeau tests, ultrasounds, and lab reviews. Informed consent was obtained during consultations or in recovery bays. Recruitment involved 30 randomized patients divided into expedited and standard protocol groups.

Pre-assignment details

No significant events, such as washout or run-in periods, occurred after participant enrollment and before group assignment. All participants who met eligibility criteria, including acceptable Barbeau test results, ultrasound evaluation, and coagulation parameters, were randomized directly into the expedited or standard protocol groups. No exclusions were reported after enrollment and prior to randomization

Participants by arm

ArmCount
Group A
TR Band 60MIN: TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
15
Group B
TR Band 120MIN: TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
15
Total30

Baseline characteristics

CharacteristicGroup AGroup BTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
6 Participants7 Participants13 Participants
Age, Categorical
Between 18 and 65 years
9 Participants8 Participants17 Participants
Age, Continuous61.5 years
STANDARD_DEVIATION 16.67
64.2 years
STANDARD_DEVIATION 11.7
62.8 years
STANDARD_DEVIATION 14.6
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants15 Participants30 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Region of Enrollment
United States
15 participants15 participants30 participants
Sex: Female, Male
Female
9 Participants7 Participants16 Participants
Sex: Female, Male
Male
6 Participants8 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 15
other
Total, other adverse events
1 / 150 / 15
serious
Total, serious adverse events
0 / 150 / 15

Outcome results

Primary

Left Radial Artery Occlusion

Reduced or absence of radial artery blood flow based on ultrasound and Barbeau test

Time frame: 30 days post procedure

Population: No patients presented with this symptom during the TR Band Procedure.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group ALeft Radial Artery Occlusion0 Participants
Group BLeft Radial Artery Occlusion0 Participants
Primary

Percentage of Participants With Bleeding

Continued ooze requiring re-inflation of the TR-Band or subcutaneous ecchymosis without a discernable hematoma

Time frame: an average of 12 hours post procedure

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group APercentage of Participants With Bleeding0 Participants
Group BPercentage of Participants With Bleeding1 Participants
Primary

Percentage of Participants With Bleeding

Continued ooze requiring re-inflation of the TR-Band or subcutaneous ecchymosis without a discernable hematoma

Time frame: 30 days post procedure

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group APercentage of Participants With Bleeding0 Participants
Group BPercentage of Participants With Bleeding1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026